National Space Society Honors JPL’s Voyager Team

Voyager 1, first to leave the solar system, continues its interstellar journey.

Twin Spacecraft are Still Pioneering the Interstellar Void 41 Years Later

The National Space Society’s Space Pioneer Award recognizes the JPL Voyager team for their amazing scientific and engineering achievements.”

— Bruce Pittman, NSS Senior Operating Officer

LOS ANGELES, CALIFORNIA, USA, April 26, 2018 /EINPresswire.com/ — For 41 years, the twin Voyager space probes, launched in 1977, have traversed the outer solar system and beyond. They carry humanity's message to the stars, etched onto gold disks carried onboard. Their journey into the depths of interstellar space will continue indefinitely.

To honor this unprecedented achievement, the National Space Society (NSS) announced today that the Jet Propulsion Laboratory team that designed, built and operated the Voyager spacecraft has been named the 2018 recipient of the NSS’s “Space Pioneer Award for Science and Engineering.”

The prestigious award will be presented to Dr. Michael Watkins, Director of the Jet Propulsion Laboratory, at the society's 37th annual International Space Development Conference, to be held at the Sheraton Gateway Los Angeles Hotel from May 24-27, 2018.

NSS Senior Operating Officer Bruce Pittman said, “The two Voyager spacecraft, launched over 40 years ago, sent back amazing pictures of the outer solar system, including Jupiter, Saturn, Uranus, Neptune, and the Saturnian moon Titan, bringing the majestic beauty of the outer planets to people around the world.”

Pittman continued, “The fact that the Voyager spacecraft are still operational and sending back useful data is a great testament to the talent of the hundreds of scientists and engineers who worked so hard to make this incredible mission possible. The National Space Society’s Space Pioneer Award recognizes the JPL Voyager team for their amazing scientific and engineering achievements.”

Also attending the conference are Blue Origin founder Jeff Bezos, famed physicist Freeman Dyson, SETI pioneer Frank Drake, Apollo 11 astronaut Buzz Aldrin, SpaceX Propulsion CTO Tom Mueller, and key members of NASA/JPL’s Cassini mission to Saturn Linda Spilker, John-Pierre Lebreton and Earl Maize. To see more on this stellar lineup of speakers, presenters and attendees, go to the ISDC website.

Past recipients of the Space Pioneer Award include:  Elon Musk, Ray Bradbury, Robert Bigelow, Apollo Astronaut Russell L. Schweickart, Dr. Michael Griffin, the Rosetta Mission Team, the Kepler-K2 Team, and the New Horizons Mission Team.

The National Space institute was founded in 1975 by NASA’s Wernher von Braun, father of the Saturn V rocket, and merged with the L5 Society, inspired by the pioneering work of Princeton physicist Gerard K. O’Neill in the same year, to create the National Space Society in 1987. It is the oldest continuously operating group striving to enable the exploration, development and settlement of space.

Aggie Kobrin
National Space Society
949-836-8464
email us here

“Humanity’s Farthest Journey.”


Source: EIN Presswire

The Pacific Mesothelioma Center is Excited to Announce the Start of Its Patient Support Group!

Mesothelioma Expert Lien Hua-Feng

LOS ANGELES, CA, U.S.A, April 26, 2018 /EINPresswire.com/ — The Pacific Mesothelioma Center (PMC) at the Pacific Heart, Lung & Blood Institute (PHLBI) is happy to announce the start of its new support group for mesothelioma patients. Nearly two years after the inception of its successful caregiver's group, the patient support group was created as a response to the growing number of individuals who expressed interest in a group centered on patients. The first meeting will be Wednesday, May 9th at 7 PM PST. The meeting will be held as a conference call every second Wednesday of the month through Uber Conference and will be moderated by PMC Nurse Practitioner and mesothelioma expert Lien Hua-Feng.

The support group will allow mesothelioma patients to discuss treatment experience with other patients, how to overcome side effects, share stories, and to ask questions about this rare cancer. Mesothelioma is an aggressive cancer caused by exposure to asbestos with few treatment options. It affects approximately 3,000 individuals in the United States each year, one-third of whom are veterans who were exposed to asbestos during military service. The rarity of this cancer limits the scope of the public’s awareness and funding for research into better treatment options.

The mission of the PMC is to generate hope through research, support, and education. The Pacific Mesothelioma Center is engaged in groundbreaking research to develop next-generation immunotherapies. PMC researchers have discovered an innovative approach to convert human mesenchymal stem cells (MSCs) into potent immune-boosting treatments that will pave the way for an entirely new class of immunotherapies that could be effective against a wide variety of cancer types, including the most aggressive ones like mesothelioma.

If you are a mesothelioma patient interested in participating on the call, please contact Christina McSherry at (310)-478-4678 or by email at christinam@phlbi.org.

Christina McSherry
The Pacific Mesothelioma Center
(310)-478-4678
email us here


Source: EIN Presswire

Speaker Interview with Pau Aceves Released – SMi’s 13th Annual ADMET conference

ADMET Event

ADMET conference an in-depth exploration of the optimisation of ADMET modelling techniques, preclinical DMPK applications and development of biopharmaceuticals.

LONDON, GREATER LONDON, UNITED KINGDOM, April 26, 2018 /EINPresswire.com/ — The event will be taking place at the Holiday Inn Kensington Forum in London, UK on the 9th and 10th July 2018.

An interview with Pau Aceves, Associate Director, Certara Strategic Consulting, has just been released and is available for download on the event website. Mr Aceves will be presenting ‘Applications of PKPD modelling in oncology – an overview’ where he will be discussing binary safety/efficacy endpoints, how patients’ individual characteristics may have as big of an impact as e.g. safety response as solely a dose, how to best manage toxicity, and PK and PKPD time-course describe via a mechanistic model.

Snapshot of Interview with Pau Aceves:

Where do you see the greatest opportunities for ADME-T leaders?

• ‘I see the advent of Machine Learning and Artificial Intelligence as a great opportunity for ADME-T leaders to automatize and increase the productivity and solve nowadays data challenges in R&D. We are nearing a point where human effort alone will no longer be able to process the quantity of data that is being generated. Hence, I believe that the Companies that are able to harness these technologies will become the leaders of drug development in decades to come.’

What are the main challenges in your day-to-day work relating to drug discovery?

• ‘I work mainly in clinical development, so one of my main challenges is the coordination with other drug discovery scientists to ensure that the required data for modelling and simulation are generated during early stages to enable translational PK/PD modelling (i.e. Pop PK/PD, PBPK and QSP).’

This year’s two-day conference will also feature over 15 expert-level speakers from organisations such as AbbVie, Roche, Bayer, GlaxoSmithKline and many more, discussing new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and much more.

To download the full interview, as well as the 2018 agenda and speaker line-up, visit the website at:
www.admet-event.com/PR1

________________________________________
Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
________________________________________

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

ADMET
9th – 10th July 2018
Holiday Inn Kensington Forum, London, UK
www.admet-event.com/PR2

Contact e-mail: ssapal@smi-online.co.uk
Contact tel: +44 (0) 207 827 6000

Follow us @SMiPharm
#SMiADMET

—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
02078276000
email us here


Source: EIN Presswire

Invite from the Chairman Hugues Malonne at SMI’s 5th Annual Molecular Diagnostics Conference

SMi proudly presents chairman Hugues Malonne, Director General, DG POST authorisation, Federal Agency for Medicines and Health Products.

LONDON, GREATER LONDON , UNITED KINGDOM, April 26, 2018 /EINPresswire.com/ — The 5th annual Molecular Diagnostics conference, will focus on evaluating the future of diagnostics for rapid detection and improved clinical outcomes.

The event will take place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshop on 11th July 2018.

Mr Malonne, who is co-chairing the two-day conference with David Crosby, Cancer Research, UK, has stated ‘As the co-chair for the event, I am particularly interested in you joining us to discuss the role of molecular diagnosis in the devolvement of personalised medicine, analyse the latest developments in companion diagnostics and discuss the future of the industry, learn what will be required in the new European In Vitro Diagnostics Regulations, assess opportunities and novel diagnostics technologies at the point-of-care, plus much more’.

On day one of the conference, Mr Malonne will be giving a presentation on ‘A National Competent Authority’s perspective on IVDR implementation’, where he will be discussing how the transition to IVDR can be supported and how to address the upcoming challenges associated.

The two-day event will feature over 16 presentations from highly-regarded, expert speakers hailing from big pharma companies, charities and medical institutions such as AstraZeneca, Cancer Research UK, Genentech and many more. The presentations will explore various topics on compliance with regulations across the globe, developing diagnostics, opportunities in point of care testing advancements in personalised medicine and much more.

Book by the 30th April to receive a £200 discount.

For the full agenda and speaker line-up, visit the website to download the brochure at www.molecular-diagnostics-conference.com/PR2
________________________________________
Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
________________________________________

For media enquiries, contact Simi Sapal, Marketing on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk
Molecular Diagnostics
9th – 10th July 2018
Holiday Inn Kensington Forum, London, UK
www.molecular-diagnostics-conference.com/PR

Contact e-mail: ssapal@smi-online.co.uk
Contact tel: +44 (0) 207 827 6000
Follow us @SMiPharm
#SMiMolecularDx

—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
2078276000
email us here


Source: EIN Presswire

Mucomel® Phase II Results Selected to be Presented at ASCO

Spherium Biomed announced today the completion of its Phase I/IIa clinical trial of Mucomel®, for the prevention and treatment of oral mucositis.

BARCELONA, SPAIN, April 26, 2018 /EINPresswire.com/ — NEWS HIGHLIGHTS
Spherium Biomed announced today the completion of its Phase I/IIa clinical trial of Mucomel®, for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemo-radiotherapy.

The trial was designed to include 84 patients with advanced disease receiving high dose radiotherapy and concomitant treatment with cisplatin or cetuximab enrolled from 11 hospitals in Spain.

The results will be presented by the leading investigator, Dr. Alicia Lozano, at the Head and Neck cancer oral abstract session of the ASCO meeting in Chicago on June 3rd.

MORE
Spherium Biomed has completed the analysis of the results of the Mucomel® trial, a phase I/IIb prospective, double blinded and placebo controlled trial to evaluate the safety and efficacy of its high dose melatonin gel, Mucomel®, for the prevention and treatment of oral mucositis (OM) in head and neck cancer patients receiving chemo-radiotherapy (NCT02630004).

The trial aimed to include 84 patients from 11 sites in Spain. The patients were selected among those scheduled to receive high dose radiation (at least 66 Gy) and concomitant cisplatin or cetuximab treatment for 2 months according to standard clinical practices for advanced grade head and neck cancer in Spain. Patients were instructed to use Mucomel® or placebo gels 5 times a day over the full course of the treatment.

The trial’s objectives were to evaluate safety and explore efficacy. The results will be fully disclosed at the oral abstract presentation of the Head & Neck Cancer track of the American Society of Clinical Oncology meeting in Chicago on June 3th according to the final program made public yesterday by the ASCO organizers (Abstract 6007, https://iplanner.asco.org/am2018/#/)

Mucositis is defined as inflammatory and/or ulcerative lesions of the gastrointestinal tract mucosa. Oral mucositis affects the oral mucosa causing erythematous and ulcerative lesions. It is particularly relevant in patients with cancer being treated with chemo- and/or radiation therapy, especially in high dose CT / RT in head and neck cancer patients. Severe oral mucositis leads to pain, changes in diet (including parenteral feeding), hospitalization and de-escalation of oncologic treatment.

There are more than 550.000 cases of Head and Neck cancer every year, and no drug is approved for the treatment or prevention of oral mucositis. The standard of care is based in pain medication and oral rinses or barrier devices to maintain mucosal integrity. Nearly 100% of patients receiving chemo and/or radio therapy will develop OM. 70% to 85% of patients receiving chemo-radio therapy will develop severe OM (Grades 3 or 4). At grade 3, the patients are in excruciating pain and cannot swallow solids; at Grade 4 the patients cannot drink and require feeding-tubes. In addition to head and neck cancer patients, 75% of patients receiving bone marrow transplantation for hematological cancer are expected to develop OM. In other types of cancer, 20-40% of patients receiving standard chemotherapy may also develop OM.

Mucomel® is based on a proprietary, patented high-load gel formulation of melatonin presented in individual 10ml sachets, to facilitate administration on out-patient basis. Spherium aims to partner the program during 2018 to complete development and reach patients worldwide as fast as possible.

ABOUT SPHERIUM (www.spheriumbiomed.com)

Spherium Biomed is a clinical-stage, biopharmaceutical portfolio company that sources its pipeline from academic research. The company applies a lean, hands-on venture builder model to advance its portfolio up to a relevant value milestone to increase the chance of academic discoveries reaching the market. The company applies its broad experience in drug development (from discovery to clinical and commercial stages) to deeply analyze the commercial potential of technologies. After defining the relevant gaps with respect to an ideal target product profile, the company acquires development and commercialization rights for the asset and derives a creative and cost-effective work plan to bring the project forward, and implements the plan with its own resources and the proactive coordination of external providers.

Spherium is privately owned; its major shareholders are its founders and key executives, and the Spanish pharmaceutical company Ferrer (www.ferrer.com). Its current portfolio includes three Phase II clinical stage projects and one Phase I. The portfolio includes several first-in-class preclinical projects as well, two of them undergoing IND-enabling regulatory safety-toxicology and industrial scaling up. The company is constantly looking for new opportunities addressing unmet clinical needs.

For more information please contact info@spheriumbiomed.com

Dr. Bill Mason
The Sage Group
+44 7785 950134
email us here


Source: EIN Presswire

Current and forthcoming Azerbaijan Energy and Utilities Construction Market size in terms of volume and value 2021

WiseGuy Market Research Report

PUNE, MAHARASHTRA, INDIA, April 26, 2018 /EINPresswire.com/ — Azerbaijan Energy and Utilities Construction Market

Synopsis 

"Energy and Utilities Construction Market in Azerbaijan: Market Size, Growth and Forecast Analytics to 2021" contains historic and forecast market data for the energy and utilities construction market in Azerbaijan, with a detailed breakdown of the data by construction activity (new construction, repair and maintenance, refurbishment and demolition) and by cost type( construction materials, construction equipment and construction services). This report also contains overall values of the energy and utilities construction segments such as Energy and utilities construction market covers the development of energy and telecommunications related projects, oil and gas projects including both upstream and downstream exploration, and utility projects such as water and sewage infrastructure. This market includes five categories: electricity and power, oil & gas, telecommunications, sewage infrastructure and water infrastructure.. This research report provides up-to-date market size data for the period 2012-2016 and an illustrative forecast to 2021.

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/2397580-energy-and-utilities-construction-market-in-azerbaijan-market-size-growth-and

Summary 
Energy and utilities construction market covers the development of energy and telecommunications related projects, oil and gas projects including both upstream and downstream exploration, and utility projects such as water and sewage infrastructure. This market includes five categories: electricity and power, oil & gas, telecommunications, sewage infrastructure and water infrastructure.

The Azerbaijani energy and utilities construction category has observed some fluctuations in the review period with a value of AZNxxx.xx million (US$xxx.xx million) in 2016 and declined at a rate of xx.xx% over 2015. The market recorded a CAGR of x.xx% from 2012 through 2016.

"Energy and Utilities Construction Market in Azerbaijan: Market Size, Growth and Forecast Analytics to 2021"' provides a top-level overview and detailed insight into the operating environment of the energy and utilities construction market in Azerbaijan. It is an essential tool for companies active across the Azerbaijan construction value chain and for new players considering to enter the market.

Scope 
• An overview of the energy and utilities construction market in Azerbaijan.

Historic (2012 through 2016) and forecast (2017 through 2021) construction market output values are provided.
A detailed breakdown of the data by construction activity (new construction, repair and maintenance, refurbishment and demolition) is provided at the market level while the values for the segments are provided by cost types (construction materials, construction equipment & construction services).
This report covers all the segments of commercial construction market including Energy and utilities construction market covers the development of energy and telecommunications related projects, oil and gas projects including both upstream and downstream exploration, and utility projects such as water and sewage infrastructure. This market includes five categories: electricity and power, oil & gas, telecommunications, sewage infrastructure and water infrastructure..
Reasons To Buy 
• Enhances your knowledge of the market with key figures detailing construction type.

Provides you with a breakdown of the market by construction activity (new construction, repair and maintenance, refurbishment and demolition).
Provides you with a breakdown of the segments by cost type (construction materials, construction equipment &construction services).
Details the segments covered under commercial construction market.
Allows you to plan future business decisions using the forecast figures given.

Table of Contents 

1 Introduction 
    1.1 What is this Report About? 
    1.2 Definitions 
    1.3 CAGR Definition and Calculation 
2 Overall Energy and Utilities Construction Value: Market Analysis 
    2.1 Overall Energy and Utilities Construction Output Value, 2012 – 2016 
    2.2 Overall Energy and Utilities Construction Output Value Forecast, 2017 – 2021 
    2.3 Overall Energy and Utilities Construction Output Value by Cost Type 
      2.3.1 Overall Energy and Utilities Construction Output Value by Cost Type, 2012 – 2016 
      2.3.2 Overall Energy and Utilities Construction Output Value Forecast, by Cost Type, 2017 – 2021 
3 Energy and Utilities Construction Output: Analysis by Category 
    3.1 New Construction Output Value, 2012 – 2016 
    3.2 New Construction Output Value Forecast, 2017 – 2021 
    3.3 New Construction Output Value by Cost Type   

  .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2397580-energy-and-utilities-construction-market-in-azerbaijan-market-size-growth-and

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Solar Rooftop Market will reach at a CAGR of 20.14%from 2017 to 2023

PUNE, MAHARASHTRA, INDIA, April 26, 2018 /EINPresswire.com/ — Solar Rooftop Market

Synopsis 

Solar photovoltaic rooftop systems are widely used to produce electricity from sun light and are mounted on top of any commercial, industrial, residential or government building. Solar rooftop systems are either grid-connected of off-grid electricity generating systems. In the on-grid solar rooftop systems, the electricity is generated from solar PV rooftop which are connected to the utility grid. However, the off-grid systems generate electricity which is consumed by the connected load, and excess of power is stored in batteries to be used as and when needed. Over the past few years, the demand for solar rooftop systems is gradually rising and expecting a remarkable growth in future. Solar rooftop systems have been dominating the renewable energy market owing to its increasing demand from its end-use applications. 
The global solar rooftop market is a very dynamic market and is expected to witness high growth over the forecast period. The growth of the solar rooftop market is majorly influenced by the growing demand for energy consumption around the world. Furthermore, electricity produced by renewable sources is clean, cost effective and renewable in nature which drives the market towards growth. However, the high capital cost for installation is acts as a major barrier for the growth of the solar rooftop market. The global solar rooftop market is expected to grow at a CAGR of 20.14%, during the forecast period. 

 Click here for sample report @ http://www.wiseguyreports.com/sample-request/2841663-global-solar-rooftop-market-trends-forecast-2017-2023

Key Players 
The key players of global solar rooftop market are SMA Solar Technology AG (Germany), Trina Solar (China), Yingli Green Energy Holding Company Limited (China), Canadian Solar Inc. (Canada), Jinko Solar (China), SolarWorld AG (Germany), SunPower Corporation (U.S.), Shunfeng International Clean Energy Limited. (China), Tata Power Solar Systems Limited (India), Delta Energy Systems (Germany), JA Solar Holdings Co., Ltd. (China) and ABB Ltd. (Switzerland).

Objective of Global Solar rooftop Market Analysis & Forecast, from 2016 to 2023 
• To provide insights about factors influencing and affecting the market growth. 
• To provide historical and forecast revenue of the market segments as well as sub-segments with respect to regional markets and their key countries 
• To provide historical and forecast revenue of the market segments based on operating system. 

Target Audience 
• Manufactures 
• Raw materials suppliers 
• Aftermarket suppliers 
• Research institute & education institute 
• Potential investors 
• Key executive (CEO and COO) and strategy growth manager

Key Findings 
• On the basis of capacity, the market is segmented as Upto 10 kW, 11 kW- 100 kW, and More than 100 kW. 11 kW- 100kW dominate the global solar rooftop market with a share of 40.3% in 2016, in terms of value. It is expected to grow at a CAGR of 21.54% during the forecast period. 
• On the basis of connectivity, the market is segmented as On-Grid, and Off-Grid. On-Grid based solar rooftop dominate the market with a share of 74.6% in 2016, in terms of value. It is expected to grow at a CAGR of 20.38% during the forecast period. 
• On the basis of end-user, the market is segmented as Residential, Commercial and Industrial. Commercial dominated the global solar rooftop market with a share of 42.4% in 2016, in terms of value. It is expected to grow at a CAGR of 21.96% during the forecast period. 

Table of Contents 

1 Executive summary 12 
2 Introduction 14 
    2.1 Definition 14 
    2.2 Scope of the Study 14 
    2.3 Assumptions 14 
    2.4 Market Structure 15 
3 Research Methodology 16 
    3.1 Research Process 16 
    3.2 Primary Research 17 
    3.3 Secondary Research 17 
    3.4 Market Size Estimation 17 
    3.5 Forecast Model 19 
4 Market Dynamics 20 
    4.1 Drivers 21 
    4.2 Restraint 24 
    4.3 Opportunity 25 

  .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2841663-global-solar-rooftop-market-trends-forecast-2017-2023

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Precision Medicine – Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022

Precision Medicine Market 2018–By Identifying the Key Market Segments and Key players holding market share

PUNE , INDIA, April 26, 2018 /EINPresswire.com/ — Report Description
Introduction
The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ‘Precision Medicine Initiative’ by the president Barack Obama in January end, 2015, a large number of research and developments are being done for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic area affected by genetic mutations.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/826425-global-precision-medicine-market-estimate-and-forecast-through-2015-2022

The global precision medicine market is expected to reach $ 88 billion by 2022 at a CAGR of 12.0% during the forecast period.
On the basis of sub-markets, Pharmacogenomics is by far the fastest growing segment of global precision medicine market and it is expected to reach $12.0 billion by 2022.
Based on therapeutics, cancer commands the largest market share of global precision medicine market and it is expected to grow at a CAGR of 11.8% during the period 2015 to 2022.
The Americas dominated the global market in 2014 and accounted for $20.63 billion due to the advancement of gene mapping technologies and increasing precision medicine solutions.
Europe and APAC are estimated to show a high growth by the end of forecast period, where large numbers of developments in precision medicine have been noticed in the last few years are. In addition to this, APAC region is also predicted to grow at the highest CAGR of 14.34% from 2015 to 2022.

Key Players
The leading market players in the global precision medicine market include; Abbott Laboratories (U.S), Almac Group, Ltd. (U.K.), ASURAGEN, Inc. (U.S.), bioMérieux SA (France), Cepheid Inc. (U.S.), GE Healthcare (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.) and others.  

STUDY OBJECTIVES OF PRECISION MEDICINE MARKET DEVELOPMENT AND DEMAND FORECAST TO 2022 MARKET
Ø To provide insights about factors, influencing and affecting the market growth.
Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.
Ø To provide historically and forecast revenue of the market segments based on products, and sub-segment for global precision medicine market.
Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
Ø To provide economic factors that influence the global precision medicine market.

Target Audience
• Pharmaceutical companies
• Research Laboratories
• Hospitals & Clinics
• Service Suppliers
• Potential Investors
• Key executive (CEO and COO) and strategy growth manager

Key Findings
• Americas dominated the global precision medicine market in 2015; however, it is expected to grow at a CAGR of 11.6% during 2015 – 2022.
• The companion diagnostics segment holds the largest share, with $10 billion value of the total market in 2015; while it is expected to reach $21.3 billion in 2022, at a CAGR of 13.4% for the period 2015-2022.
• The cancer segments hold the largest share, with $21.1 billion value, of the total market in 2015; while it is expected to reach $46.3 billion in 2022, at a CAGR of 11.8% for the period 2015 – 2022.
• Abbott Laboratories (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.), are so far the leading market players for precision medicine market globally

Regional and Country Analysis of precision medicine Market Development and Demand Forecast to 2022 Market
As per the analysis, the Americas precision medicine market is poised to reach $49.3 billion by 2022, to grow at a CAGR of around XX% during the forecasted period. The European market was valued at $ 9.2 billion in 2015, and expected to reach at $ 21.9 billion by 2022. Asia-Pacific continues to be the fastest growing region during the forecast period.

Table of Content: Key Points
1 REPORT SCOPE 26
2 EXECUTIVE SUMMARY 38
3 MARKET OVERVIEW 42
4 MARKET DYNAMICS 61
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/826425-global-precision-medicine-market-estimate-and-forecast-through-2015-2022

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Articaine Hydrochloride Market – What's New Trending For 2018 – 2021?

Articaine Hydrochloride Market 2018 by Current & Upcoming Trends

PUNE , INDIA, April 26, 2018 /EINPresswire.com/ — Articaine is a form of an amide local anesthetic that is most commonly used in dentistry. The chemical name for articaine hydrochloride is 2-Thiophenecarboxylic acid-4-methyl-3- ((1-oxo-2-(propyl amino) propyl) amino)-methyl ester hydrochloride (C13H21ClN2O3S). The CAS Number is 23964-57-0. It is a white or almost white crystalline powder with the molecular weight of 320.84 g/mol. This drug is originally known as carticaine. It has different molecular structure with a thiophene ring instead of the usual benzene ring present in the other amide anesthetic drugs. The half-life of Articaine is 1.8 hours. Like other amide anesthetics it blocks nerve conduction when it is inflated around a nerve. The action of articaine can be prolonged by combining it with a vasoconstrictor such as adrenaline. If needed, stock solutions can be created in advanced and can be stored as aliquots in tightly sealed vials at -20°C. The Articaine is marketed as a colourless liquid in vials/cartridges (2ml in each vial/cartridge). The Articaine is available in two variants i.e. Articaine-100 & Articaine-200. Articaine-200 is more potent than Articaine-100.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1706448-global-articaine-hydrochloride-market-analysis-forecast-2016-to-2021

The dosage can be based on type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. For paediatric patients, dosage based on their age, weight, physical condition of the patient and extent of surgical procedure.

The global market of articaine hydrochlorides is expected to reach USD 1363.0 million by 2021, at a CAGR of 7.0% during the forecast period.

Based on application of articaine hydrochloride, the nerve block segment is by far the fastest growing segment of global articaine hydrochloride market and it is expected to reach USD 624.8 million by 2021.
Based on end users of articaine hydrochloride, the dental clinics segment commands the largest market share of global articaine hydrochloride market and it is expected to grow at a CAGR of 7.1% during the period 2016 to 2021.
Today's availability of a variety of local anesthetics enabled dentists to select an anesthetic which has specific properties like time of onset and its duration, hemostatic control, degree of cardiac or neurotoxic side effects that are appropriate specific dental procedures for each individual patient. Articaine with its greater ability to diffuse through tissues become a very widely used local anesthetic in the European and Canadian markets. The US market is growing steadily. Articaine is the second most used local anesthetic in the United States. In U.S. articaine share is around 40%. In Canada, Articaine hydrochloride is the number one choice of the dentists.

Articaine hydrochloride is most popular local anesthetic for dentistry in a number of European countries. Germany is the biggest buyer of Articaine hydrochloride. In Germany, 97% of the anesthetic used by dentists is articaine hydrochloride. In Italy and France articaine is most used by dentists.
In Australia, around 70% of the dentists use articaine as local anesthetic. In Asian countries, China is one of the biggest producers of Articaine hydrochloride and its products are mostly exported to Middle-East and European regions. Thus, Articaine hydrochloride is being used increasingly by the medical professional nowadays.

Key Players
The leading market players in the global articaine hydrochloride market include; 3M, Anhui BBCA Pharmaceutical Co., Ltd., Dentsply Sirona, Inibsa Dental S.L.U, Jinan Chenghui Shuangda Chemical Co., Ltd, Jinan Ruixing Pharmaceutical Technology Co., Ltd, Manus Aktteva Biopharma LLP, Pfizer Inc, Pierrel S.p.A, Sanofi, Septodont, Siegfried AG, Sigma Aldrich and many others. 

Study Objectives
Ø To provide insights about factors, influencing and affecting the market growth.
Ø To provide historical and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.
Ø To provide historical and forecast revenue of the market segments based on application, and end users for global articaine hydrochloride market.
Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
Ø To provide economic factors that influences the global articaine hydrochloride market.

Target Audience
Ø Articaine hydrochloride manufacturers
Ø Articaine API manufacturers
Ø Articaine hydrochloride suppliers
Ø Research Laboratories
Ø Hospitals & Clinics
Ø Service Suppliers
Ø Potential Investors
Ø Key executive (CEO and COO) and strategy growth manager

Key Findings
• The global market for articaine hydrochloride is expected to grow at a CAGR of 7.0% during the period 2016 to 2021 to reach USD 1363.0 million by 2021.
• The articaine hydrochloride market in Asia is expected to grow rapidly during 2016 to 2021 whereas Europe will remain the largest market by 2021.
• The global market for articaine hydrochloride by application, infiltration segment is expected to witness highest CAGR of 6.9% during the period 2016 to 2021.
• Based on the end users, dental clinics segment commands the largest market share of global articaine hydrochloride market; registered 7.1% share in 2015

Table of Content: Key Points
1 Report Prologue 15
2 Global Scenario of Oral Health 18
3 Scope of Study 24
4 Research Methodology 26
5 Market Dynamics 28
6 Market Factor Analysis 32
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1706448-global-articaine-hydrochloride-market-analysis-forecast-2016-to-2021

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

IQ4I Research & Consultancy published a new report on “Pharmaceutical Excipients Global Market – Forecast To 2022”

Excipients are inactive substances that modulate solubility, bioavailability and stability of active substances in a drug. Novel excipients are in great demand.

Pharmaceutical Excipients Global Market estimated to be worth $7,716 million by 2022”

— IQ4I Analyst

BOSTON , MASSACHUSETTS, U.S., April 26, 2018 /EINPresswire.com/ — Excipients are a broad range of non-active components combined with active pharmaceutical ingredient (API) during formulation to form a desired finished drug product and perform a wide range of functions. It is usually identified as a substance that aid to function API with better functionality such as bioavailability, stability, good taste, texture and patient acceptability with safety and efficacy of pharmaceuticals to improve the quality-of-life of the patient at a lower cost. In fact, a few decades ago, excipients were not considered important due to their inactive nature, but now they are considered as one of the essential components in the production of tablets, liquid orals, powders, semi-solids and parenteral as excipients impact the stabilization of drug product in various conditions such as change in pressure, temperature, pH etc. Oral (tablets and capsule) dosage forms are mostly preferred due to ease of manufacturing and patient compliance and the development of these oral dosage forms involves direct compression and granulation process. The majority of vertically integrated companies develop in-house excipients and small formulators often rely on external suppliers to outsource specialised co-processed functionality excipients.

Presently, there is demand for the development of novel excipients with technological advancements like new chemical entity excipients, new chemically modified grade excipients, existing excipients with the various route of administration and co-processed excipients. These novel excipients increase the scope for the development of new formulations and drug delivery system which is a major gain for the industry, but high cost and lengthy developmental process along with the safety and quality issues are delaying the excipients approval. Combination excipients are mostly preferred by the manufacturers as the single excipients do not meet all the functional requirements such as high solubility, stability and bioavailability. As estimated by IQ4I Research, the global pharmaceutical excipients market is expected to grow at mid range single digit CAGR to reach $7,716 million by 2022.

Development of highly soluble excipients for sustained and controlled release formulations, global pharmaceutical excipient outsourcing, manufacturing of co-processed excipients using nano- and liposome-mediated technologies, strategic partnership/alliance among excipient manufacturers are some of the factors driving pharmaceutical excipient market whereas less interest in developing novel excipients, contamination issues in formulations, and delay in approval of novel excipients are the factors restraining market growth. Recently in 2015, IPEC-Americas calls FDA to review process for novel excipients and create new regulations to relieve the uncertainties around the use of new excipients. The most commonly used excipients in the small molecule are carbohydrates, oleochemicals, petrochemicals, metallic oxides, silicates etc whereas in large molecules sodium salts, solvents, emulsifiers and amino acids etc are used.

The pharmaceutical excipients market is mainly classified into source/origin, material type, manufacturing process, functionality, application, finished products and geography. The pharmaceutical excipient source/origin market includes animal-, plant-, mineral- and synthetic-based excipients. By material type the pharmaceutical excipient is classified into inorganic chemicals, organic chemicals and others. Inorganic chemical segment divided into calcium salts, halites, metallic oxides, silicates and others. Likewise, organic chemicals are further divided into carbohydrates including sugar (actual sugar, sugar alcohol, artificial sweetener), starch (modified, converted, dried) and cellulose (cellulose ether, cellulose ester, croscarmellose sodium, microcrystalline cellulose), petrochemicals including glycol (polyethylene, propylene glycol), povidone, mineral hydrocarbons (petrolatum, mineral waxes, mineral oils), acrylic polymers, others (antimicrobials, antioxidants, dyes & lakes), oleochemicals including fatty alcohol, mineral stearate, glycerin and others (alcohol, citric acid, lactic acid, polysaccharide gums, Shellac), proteins including gelatin and others including water for injection and purified water.
The pharmaceutical excipients manufacturing process market includes granulation and direct compression. The pharmaceutical excipient by functionality is segmented into fillers & diluents, binders & adhesives, suspension & viscosity agents, coatings, colorants, flavoring agents & sweeteners, disintegrants, lubricants & glidants, preservatives, solvents, solubilizers and others (anti-adherents, buffering agents, chelating agents, compression aids, foam control agents, sorbents, antioxidants, gelling agents, emulsifiers, emollients & humectants and plasticizers).

The pharmaceutical excipients by the application is divided into oral formulations (tablets, capsules & liquids), topical, parenteral and advanced delivery system. By finished products, the excipient market is classified into prescription and over-the-counter.

Geographical wise, North America is the largest market followed by Europe, Asia and Rest of the World. The Asia Pacific region is the fastest growing region with a highest single digit CAGR from 2015 to 2022 suggesting an array of opportunities for growth and likely to be getting into the eyes of new investors in the pharmaceutical excipients market.

The pharmaceutical excipients global market is a highly fragmented market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the pharmaceutical excipient market are Ashland, Inc (U.S.), Associated British Foods Plc (U.K.), Avantor Performance Materials, Inc (U.S.), BASF SE (Germany), Croda International Plc (U.K.), Dow Chemical Company (U.S.), Evonik Industries AG (Germany), FMC Corporation (U.S.), Lubrizol Corporation (U.S.) and Roquette (France).

Mr. Satish Birudukota
IQ4I Research & Consultancy Pvt Ltd.,
+91-80-8147030229
email us here


Source: EIN Presswire